SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for use within NHS Scotland as a first-line treatment for adults with advanced non-small cell lung cancer (NSCLC) carrying common EGFR mutations. The decision applies to previously untreated patients whose tumours have EGFR exon 19 deletions or exon 21 L858R substitution […] The post SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer appeared first on Pharmafile.

Continue reading →